The United States Medical Research Institute of Infectious Disease (USAMRIID) is seeking contract support for the evaluation of the mechanism of action (MOA) of potential therapeutic countermeasures which can be used to treat ebolavirus infection.
The Virology Division within USAMRIID has screened sets of FDA-approved drugs to test against ebolavirus in in vitro assays. In order to better understand the MOAs, various assays to evaluate the various stages of virus replication are necessary. The contractor shall utilize artificial ebolavirus minigenome system to test the ability of compounds to block gene expression, which will aid in identifying effective therapeutics against these viruses.
USAMRIID will provide access to their drug library for the duration of the research. Further details are available under Solicitation Number: W81XWH-14-X-0000.
